Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
8.27
-0.27 (-3.16%)
At close: Jul 10, 2026, 4:00 PM EDT
8.28
+0.01 (0.12%)
After-hours: Jul 10, 2026, 6:30 PM EDT
Arvinas Revenue
Arvinas had revenue of $15.60M in the quarter ending March 31, 2026, a decrease of -91.74%. This brings the company's revenue in the last twelve months to $89.40M, down -79.06% year-over-year. In the year 2025, Arvinas had annual revenue of $262.60M, down -0.30%.
Revenue (ttm)
$89.40M
Revenue Growth
-79.06%
P/S Ratio
5.97
Revenue / Employee
$363,415
Employees
246
Market Cap
533.59M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 262.60M | -800.00K | -0.30% |
| Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
| Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
| Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
| Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
| Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
| Dec 31, 2019 | 43.00M | 28.68M | 200.20% |
| Dec 31, 2018 | 14.32M | 6.75M | 89.00% |
| Dec 31, 2017 | 7.58M | 909.86K | 13.64% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sutro Biopharma | 99.61M |
| Assembly Biosciences | 71.10M |
| XOMA Royalty | 48.56M |
| Editas Medicine | 38.69M |
| Crescent Biopharma | 11.88M |
| Shattuck Labs | 1.00M |
| ProKidney | 889.00K |
ARVN News
- 17 days ago - Arvinas Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Arvinas Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Arvinas to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Arvinas Employees Give Back During Company-wide Impact Day - GlobeNewsWire
- 2 months ago - Arvinas price target raised to $16 from $14 at BofA - TheFly
- 2 months ago - Arvinas price target raised to $18 from $16 at BTIG - TheFly
- 2 months ago - Arvinas price target raised to $20 from $18 at Barclays - TheFly
- 2 months ago - H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’ - TheFly